Lung cancer: New biological insights and recent therapeutic advances (Q46049056)

19 December 2017

title

Lung cancer: New biological insights and recent therapeutic advances (English)

1 reference

19 December 2017

1 reference

2

1 reference

19 December 2017

Fadlo R Khuri

series ordinal

3

object named as

Fadlo R Khuri

1 reference

19 December 2017

author name string

Suresh S Ramalingam

series ordinal

1

1 reference

19 December 2017

language of work or name

English

0 references

publication date

8 February 2011

1 reference

19 December 2017

published in

CA

1 reference

19 December 2017

volume

61

1 reference

19 December 2017

issue

2

1 reference

19 December 2017

page(s)

91-112

1 reference

19 December 2017

Global patterns of cancer incidence and mortality rates and trends

cites work

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Lung cancer incidence in never smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Diversity of gene expression in adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Molecular characteristics of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

The new World Health Organization classification of lung tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Involvement of LKB1 in epithelial-mesenchymal transition (EMT) of human lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Small adenocarcinoma of the lung. Histologic characteristics and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Stepwise progression of pulmonary adenocarcinoma--clinical and molecular implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Mortality in relation to smoking: 40 years' observations on male British doctors

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Cancer, cigarette smoking and premature death in Europe: a review including the Recommendations of European Cancer Experts Consensus Meeting, Helsinki, October 1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

A gene expression signature predicts survival of patients with stage I non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Prediction of lymph node metastasis by analysis of gene expression profiles in primary lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

A variant associated with nicotine dependence, lung cancer and peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

International Lung Cancer Consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Polymorphisms in xenobiotic conjugation and disease predisposition

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Molecular epidemiology of smoking and lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

How many tumor suppressor genes are involved in human lung carcinogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

A mouse model for EML4-ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

DNA methylation markers and early recurrence in stage I lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Advances in understanding cancer genomes through second-generation sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

New approaches to the minimally invasive treatment of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Stereotactic body radiation therapy for inoperable early stage lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Radiofrequency ablation for the treatment of stage I non-small cell lung cancer in high-risk patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-c

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

The effect of FDG-PET on the stage distribution of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

State-of-the-art chemotherapy for advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

The EGFR as a target for anticancer therapy--focus on cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Molecular and biological properties of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Surgical resection for lung cancer in the octogenarian

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated?

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Prophylactic cranial irradiation in extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.20102

21 January 2018

Identifiers

DOI

10.3322/CAAC.20102

1 reference

19 December 2017

1 reference

19 December 2017